A Closer Look At Kala Pharmaceuticals Inc. (KALA)’s Financials

At the last check on Thursday, Kala Pharmaceuticals Inc.’s (NASDAQ:KALA) stock was down -$0.01, moving down -1.12 percent to $0.37. The average number of shares traded per day over the past five days has been 1,096,491 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0171 fall in that time frame. In the last twenty days, the average volume was 2,097,153, while in the previous 50 days, it was 1,644,903.

Since last month, KALA stock retreated -41.93%. Shares of the company fell to $0.3400 on 06/13/22, the lowest level in the past month. A 52-week high of $6.11 was reached on 03/16/22 after having rallying from a 52-week low of $0.34. Since the beginning of this year, KALA’s stock price has dropped by -68.98% or -$0.8383, and marked a new high 6 times. However, the stock has declined by -93.92% since its 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Kala Pharmaceuticals Inc. (KALA) last reported insider trading activity 28 days ago on May 26. RA CAPITAL MANAGEMENT, L.P., the 10% Owner of the company, disposed of 1,005,686 shares for $0.36 on May 26. It resulted in a $365,667 divestment by the insider. RA CAPITAL MANAGEMENT, L.P. sold 1,434,509 shares at an average price of $0.42 on May 25. The insider now owns 8,045,299 shares following the transaction. On May 24, 10% Owner RA CAPITAL MANAGEMENT, L.P. sold 144,805 shares at $0.51 apiece. The transaction was valued at $73,851.

Financial Health

In the three months ended December 30, Kala Pharmaceuticals Inc.’s quick ratio stood at 2.70, while its current ratio was 3.00, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 55.90% percent. Based on annual data, KALA earned $7.14 million in gross profit and brought in $11.24 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -140.40%. Return on equity (ROE) for the past 12 months was -369.20%.

In Kala Pharmaceuticals Inc.’s quarter-end financial report for December 30, it reported total debt of $79.36 million against cash and short-term investments of $4.99 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. KALA’s revenue fell -138.69% to $1.86 million during the quarter, while net income inched up to $1.37 million. While analysts expected Kala Pharmaceuticals Inc. to report -$0.41 quarterly earnings, the actual figure was -$0.68 per share, beating the consensus estimate by -65.90%. During the quarter, the company generated -$30.32 million in EBITDA. The liabilities of Kala Pharmaceuticals Inc. were 116.86 million at the end of its most recent quarter ended December 30, and its total debt was $80.19 million. The value of shareholders’ equity is $72.59 million.

Technical Picture

This quick technical analysis looks at Kala Pharmaceuticals Inc.’s (KALA) price momentum. With a historical volatility rate of 106.82%, the RSI 9-day stood at 39.82% on 22 June.

With respect to its five-day moving average, the current Kala Pharmaceuticals Inc. price is down by -4.40% percent or -$0.0171. At present, KALA shares trade -21.76% below its 20-day simple moving average and -52.88% percent below its 100-day simple moving average. However, the stock is currently trading approximately -61.29% below its SMA50 and -88.67% below its SMA200.

Stochastic coefficient K was 36.37% and Stochastic coefficient D was 43.77%, while ATR was 0.0414. Given the Stochastic reading of 35.62% for the 14-day period, the RSI (14) reading has been calculated as 36.57%.

Analyst Ratings

Kala Pharmaceuticals Inc. downgraded its rating on Kala Pharmaceuticals Inc. (NASDAQ: KALA) to an Underweight in a note to investors on March 30, 2022. The analysts firm previously had a Neutral rating on the stock.Kala Pharmaceuticals Inc. (KALA) has been rated Overweight by analysts. According to 1 brokerage firm, KALA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Kala Pharmaceuticals Inc. stock as buy, with 4 recommending it as overweight.

With a median target price of $3.00, the current consensus forecast for the stock is $1.75 – $4.00. Based on these forecasts, analysts predict Kala Pharmaceuticals Inc. (KALA) will achieve an average price target of $2.95.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles

174452

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam